US FDA approves Emergent's smallpox vaccine for people at high risk of mpox
Updates with details and background from paragraph 2
Aug 29 (Reuters) -The U.S. Food and Drug Administration (FDA) has approved expanded use of Emergent BioSolutions' EBS.N ACAM2000 smallpox vaccine to include people at high risk for mpox infection, the company said on Thursday.
Earlier this month, the World Health Organization declared mpox a global public health emergency for the second time in two years as a new variant of the virus, known as clade Ib, spread rapidly in Africa.
The FDA's approval follows Emergent's application for an Emergency Use Listing of ACAM2000 vaccine with the WHO.
Emergent last week said it would donate 50,000 doses of its smallpox vaccine to the Democratic Republic of the Congo and other impacted countries of Burundi, Kenya, Rwanda and Uganda to address the mpox outbreak.
According to the U.S. Centers for Disease Control and Prevention, ACAM2000 has more known side effects and risks than Danish biotech Bavarian Nordic A/S's BAVA.CO Jynneos vaccine, which is approved in the United States for both smallpox and mpox.
ACAM2000 - a live, replicating virus vaccine - is known to cause myocarditis/pericarditis - swelling in or around the heart muscle - in 1 in 175 new ACAM2000 vaccine recipients, according to the FDA.
Reporting by Shivani Tanna in Bengaluru; Editing by Maju Samuel and Subhranshu Sahu
Latest News
Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.
All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.
Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.
